BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 23642239)

  • 21. Treatment of medulloblastoma with oncolytic measles viruses expressing the angiogenesis inhibitors endostatin and angiostatin.
    Hutzen B; Bid HK; Houghton PJ; Pierson CR; Powell K; Bratasz A; Raffel C; Studebaker AW
    BMC Cancer; 2014 Mar; 14():206. PubMed ID: 24646176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncolytic Activity of a Novel Influenza A Virus Carrying Granulocyte-Macrophage Colony-Stimulating Factor in Hepatocellular Carcinoma.
    Penghui Y; Fang S; Ruilan W; Guanglin L; Hongjing G; Yueqiang D; Zhongpeng Z; Xiaolan Y; Zhaohai W; Shaogeng Z; Xiliang W
    Hum Gene Ther; 2019 Mar; 30(3):330-338. PubMed ID: 30205709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model.
    Lee JH; Roh MS; Lee YK; Kim MK; Han JY; Park BH; Trown P; Kirn DH; Hwang TH
    Cancer Gene Ther; 2010 Feb; 17(2):73-9. PubMed ID: 19629143
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.
    Liu C; Hasegawa K; Russell SJ; Sadelain M; Peng KW
    Prostate; 2009 Jul; 69(10):1128-41. PubMed ID: 19367568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oncolytic measles virus strains as novel anticancer agents.
    Msaouel P; Opyrchal M; Domingo Musibay E; Galanis E
    Expert Opin Biol Ther; 2013 Apr; 13(4):483-502. PubMed ID: 23289598
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemovirotherapy of malignant melanoma with a targeted and armed oncolytic measles virus.
    Kaufmann JK; Bossow S; Grossardt C; Sawall S; Kupsch J; Erbs P; Hassel JC; von Kalle C; Enk AH; Nettelbeck DM; Ungerechts G
    J Invest Dermatol; 2013 Apr; 133(4):1034-42. PubMed ID: 23223133
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncolytic measles virus enhances antitumour responses of adoptive CD8
    Chen A; Zhang Y; Meng G; Jiang D; Zhang H; Zheng M; Xia M; Jiang A; Wu J; Beltinger C; Wei J
    Sci Rep; 2017 Jul; 7(1):5170. PubMed ID: 28701757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism.
    Leber MF; Bossow S; Leonard VH; Zaoui K; Grossardt C; Frenzke M; Miest T; Sawall S; Cattaneo R; von Kalle C; Ungerechts G
    Mol Ther; 2011 Jun; 19(6):1097-106. PubMed ID: 21468006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncolytic viral therapy with a combination of HF10, a herpes simplex virus type 1 variant and granulocyte-macrophage colony-stimulating factor for murine ovarian cancer.
    Goshima F; Esaki S; Luo C; Kamakura M; Kimura H; Nishiyama Y
    Int J Cancer; 2014 Jun; 134(12):2865-77. PubMed ID: 24265099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Measles virus for cancer therapy.
    Russell SJ; Peng KW
    Curr Top Microbiol Immunol; 2009; 330():213-41. PubMed ID: 19203112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter.
    Msaouel P; Iankov ID; Allen C; Aderca I; Federspiel MJ; Tindall DJ; Morris JC; Koutsilieris M; Russell SJ; Galanis E
    Mol Ther; 2009 Dec; 17(12):2041-8. PubMed ID: 19773744
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncolytic viruses for induction of anti-tumor immunity.
    Tong AW; Senzer N; Cerullo V; Templeton NS; Hemminki A; Nemunaitis J
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1750-60. PubMed ID: 21740355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunization with a syngeneic tumor infected with recombinant vaccinia virus expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) induces tumor regression and long-lasting systemic immunity.
    McLaughlin JP; Abrams S; Kantor J; Dobrzanski MJ; Greenbaum J; Schlom J; Greiner JW
    J Immunother; 1997 Nov; 20(6):449-59. PubMed ID: 9409450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic potential of oncolytic measles virus: promises and challenges.
    Galanis E
    Clin Pharmacol Ther; 2010 Nov; 88(5):620-5. PubMed ID: 20881957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors.
    Pesonen S; Diaconu I; Cerullo V; Escutenaire S; Raki M; Kangasniemi L; Nokisalmi P; Dotti G; Guse K; Laasonen L; Partanen K; Karli E; Haavisto E; Oksanen M; Karioja-Kallio A; Hannuksela P; Holm SL; Kauppinen S; Joensuu T; Kanerva A; Hemminki A
    Int J Cancer; 2012 Apr; 130(8):1937-47. PubMed ID: 21630267
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An immunocompetent murine model for oncolysis with an armed and targeted measles virus.
    Ungerechts G; Springfeld C; Frenzke ME; Lampe J; Parker WB; Sorscher EJ; Cattaneo R
    Mol Ther; 2007 Nov; 15(11):1991-7. PubMed ID: 17712331
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Measles to the Rescue: A Review of Oncolytic Measles Virus.
    Aref S; Bailey K; Fielding A
    Viruses; 2016 Oct; 8(10):. PubMed ID: 27782084
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme.
    Phuong LK; Allen C; Peng KW; Giannini C; Greiner S; TenEyck CJ; Mishra PK; Macura SI; Russell SJ; Galanis EC
    Cancer Res; 2003 May; 63(10):2462-9. PubMed ID: 12750267
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model.
    Mader EK; Maeyama Y; Lin Y; Butler GW; Russell HM; Galanis E; Russell SJ; Dietz AB; Peng KW
    Clin Cancer Res; 2009 Dec; 15(23):7246-55. PubMed ID: 19934299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition.
    Jennings VA; Scott GB; Rose AMS; Scott KJ; Migneco G; Keller B; Reilly K; Donnelly O; Peach H; Dewar D; Harrington KJ; Pandha H; Samson A; Vile RG; Melcher AA; Errington-Mais F
    Mol Ther; 2019 Jun; 27(6):1139-1152. PubMed ID: 31053413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.